Vergelijking
Leuprorelin vs. Pasireotid
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
53714-56-0
396091-73-9
Molecuulmassa
1209.4 g/mol
1047.21 g/mol
Halfwaardetijd
3 h
geen gegevens
Sequentie
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtgeen gegevens
Werkingsmechanisme
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
1
waarvan bij mensen
4
1
Geregistreerde effecten
4
2
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
3
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Leuprorelin and Pasireotid?
- Leuprorelin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Pasireotid?
- The highest available evidence level is "Humane RCT" for Leuprorelin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Pasireotid in Germany and the United States?
- Duitsland: Leuprorelin — Op recept, Pasireotid — Op recept. Verenigde Staten: Leuprorelin — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.